Becton, Dickinson & Company Platforms

Becton, Dickinson & Company (BD) is a leading global medical technology company that develops innovative solutions to enhance healthcare delivery and improve patient outcomes across various medical fields. Founded in 1897, BD specializes in the development and manufacturing of medical devices, instrument systems, and reagents. The company is headquartered in Franklin Lakes, US. In October 2010, Argon Medical Devices, a portfolio company of RoundTable Healthcare Partners, acquired BD Platforms.

Historically, BD has focused on innovation and quality to meet the evolving needs of health professionals and patients worldwide. BD specializes in medical technology, offering a comprehensive portfolio that addresses various health needs through innovation and quality. The company's core product offerings encompass solutions in areas such as Urology, Critical Care, Surgery, and Diagnostics. Their products are designed to enhance patient safety, improve clinical outcomes, and optimize healthcare operational efficiencies.

For instance, the BD Acute Urology solutions focus on advancing urological care, while their integrated diagnostic solutions streamline laboratory processes for accurate and timely results. The company caters to a diverse client base, including hospitals, clinics, laboratories, and healthcare providers across North America, Europe, and Asia-Pacific. BD's commitment to advancing health is evident in its continuous development of products that support healthcare professionals in enhancing patient care and treatment efficacy. BD reported revenue of USD 5.

5 bn, reflecting a 10. 4% increase from the previous period. The company's revenue model primarily revolves around B2B transactions, where it supplies medical devices and solutions directly to healthcare institutions and organizations. Transactions typically involve bulk orders of diagnostic equipment, surgical instruments, and medication management solutions, facilitated through established contracts with hospitals and health systems.

These agreements may include ongoing supply contracts or partnerships that ensure consistent availability of BD's flagship products, such as their hypodermic needle and syringe solutions, which are essential for various medical applications. BD’s pricing strategies align with the value delivered through their innovative offerings, further cementing their position in the medical technology sector. BD aims to continue its expansion by designing and launching new products that target unmet health needs. The company is actively exploring growth into emerging markets, particularly in Asia-Pacific and Latin America, with plans for an accelerated entry by 2025.

The acquisition by Argon Medical Devices in October 2010 has positioned BD to utilize its resources to enhance product development and market reach, thus supporting their strategic initiatives for growth.